Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of efficacy and safety of terazosin in patients with benign prostatic hyperplasia with lower urinary tract symptoms
KCT0005278Phase 4Not yet recruiting
- Sponsor
- Il-Yang Pharmaceutical
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of terazosin in benign prostatic hyperplasia (BPH), sponsored by Il-Yang Pharmaceutical. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
terazosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on KCT0005278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005278.